These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8708586)

  • 1. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study.
    Lindholm LH; Ekbom T; Dash C; Isacsson A; Scherstén B
    J Intern Med; 1996 Jul; 240(1):13-22. PubMed ID: 8708586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group.
    Johannesson M; Borgquist L; Jönsson B; Lindholm LH
    J Intern Med; 1996 Jul; 240(1):23-9. PubMed ID: 8708587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
    Morris R; Robinson G; Tilyard M; Gurr E
    N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of health care advice given in primary care on cardiovascular risk. CELL Study Group.
    Lindholm LH; Ekbom T; Dash C; Eriksson M; Tibblin G; Scherstén B
    BMJ; 1995 Apr; 310(6987):1105-9. PubMed ID: 7742677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease.
    Bak AA; Huizer J; Leijten PA; Rila H; Grobbee DE
    J Intern Med; 1998 Nov; 244(5):371-8. PubMed ID: 9845852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
    Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
    JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
    Eriksson M; Hådell K; Holme I; Walldius G; Kjellström T
    J Intern Med; 1998 May; 243(5):373-80. PubMed ID: 9651560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
    JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
    Alemao E; Yin D; Sintonen H; Salomaa V; Jousilahti P
    Am J Cardiovasc Drugs; 2006; 6(5):349-55. PubMed ID: 17083270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
    Lewis SJ; Moye LA; Sacks FM; Johnstone DE; Timmis G; Mitchell J; Limacher M; Kell S; Glasser SP; Grant J; Davis BR; Pfeffer MA; Braunwald E
    Ann Intern Med; 1998 Nov; 129(9):681-9. PubMed ID: 9841599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
    N Engl J Med; 1998 Nov; 339(19):1349-57. PubMed ID: 9841303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program.
    Guthrie RM
    Clin Ther; 2001 Jun; 23(6):970-80. PubMed ID: 11440296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group.
    MacMahon S; Sharpe N; Gamble G; Hart H; Scott J; Simes J; White H
    Circulation; 1998 May; 97(18):1784-90. PubMed ID: 9603532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
    Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of a physician-directed treatment program for low-income patients with high blood cholesterol: the Southeast Cholesterol Project.
    Keyserling TC; Ammerman AS; Davis CE; Mok MC; Garrett J; Simpson R
    Arch Fam Med; 1997; 6(2):135-45. PubMed ID: 9075448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.